We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




MicroRNA Could Help Diagnose Mental Disorders

By LabMedica International staff writers
Posted on 02 Jul 2014
The link between dysregulated serotonergic activity and depression and anxiety disorders is well established, yet the molecular mechanisms underlying these psychopathologies are not fully understood.

The etiology of depression and/or anxiety disorders is a complex interaction between environmental factors and genetic predisposition, possibly suggesting a mechanistic role for epigenetic processes, and such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease.

Scientists at the Weizmann Institute of Science (Rehovot, Israel) investigated the molecular mechanisms of the brain's serotonin system, which, when misregulated, is involved in depression and anxiety disorders. More...
They explored the role of micro ribonucleic acid (miRNA) molecules in the nerve cells that produce serotonin.

Total RNA was isolated using the PAXgene Blood RNA Kit (QIAGEN; Valencia, CA, USA) from both mice and human subjects. The team identified for the first time, the unique "fingerprints" of a microRNA molecule that acts on the serotonin-producing nerve cells. Combining bioinformatics methods with experiments, they found a connection between a particular microRNA, miR135, and two proteins that play a key role in serotonin production and the regulation of its activities. The scientists noted that in the area of the brain containing the serotonin-producing nerve cells, miR135 levels increased when antidepressant compounds were introduced.

The investigators found that subjects who suffered from depression had unusually low miR135 levels in their blood. On closer inspection, the scientists discovered that the three genes involved in producing miR135 are located in areas of the genome that are known to be associated with risk factors for bipolar mood disorders. The authors concluded that their findings suggest that miR135 could be a useful therapeutic molecule, both as a blood test for depression and related disorders, and as a target whose levels might be raised in patients. The study was published on June 19, 2014, in the journal Neuron.

Related Links:

Weizmann Institute of Science
QIAGEN



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.